临床儿科杂志 ›› 2024, Vol. 42 ›› Issue (3): 177-181.doi: 10.12372/jcp.2024.24e0003
• 述评 • 下一篇
殷勇, 陈健德
收稿日期:
2024-01-01
出版日期:
2024-03-15
发布日期:
2024-03-06
YIN Yong, CHEN Jiande
Received:
2024-01-01
Online:
2024-03-15
Published:
2024-03-06
摘要:
2023年7月以来我国乃至全球迎来了肺炎支原体肺炎的流行高峰,给儿童健康、家庭及社会均带来了沉重的负担。尽管大环内酯类抗菌药物为指南推荐的首选用药,本次流行的肺炎支原体肺炎住院患儿中,以大环内酯类耐药为主。这对传统的诊疗模式带来了巨大的挑战,特别是肺动脉栓塞病例的增多,需要临床医师思考并实践新的诊疗理念。
殷勇, 陈健德. 儿童大环内酯类耐药肺炎支原体肺炎诊疗理念与实践[J]. 临床儿科杂志, 2024, 42(3): 177-181.
YIN Yong, CHEN Jiande. Diagnosis and treatment philosophy and practice of macrolide-resistant Mycoplasma pneumoniae pneumonia in children[J]. Journal of Clinical Pediatrics, 2024, 42(3): 177-181.
[1] |
Chen J, Yin Y, Zhao L, et al. Mycoplasma pneumoniae infection prediction model for hospitalized community-acquired pneumonia children[J]. Pediatr Pulmonol, 2021, 56(12): 4020-4028.
doi: 10.1002/ppul.v56.12 |
[2] |
Baer G, Engelcke G, Abele-Horn M, et al. Role of Chlamydia pneumoniae and Mycoplasma pneumoniae as causative agents of community-acquired pneumonia in hospitalised children and adolescents[J]. Eur J Clin Microbiol Infect Dis, 2003, 22(12): 742-745.
doi: 10.1007/s10096-003-1037-9 |
[3] | 中华人民共和国国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 中国合理用药探索, 2023, 20(3): 16-24. |
[4] |
Xiao L, Ptacek T, Osborne JD, et al. Comparative genome analysis of Mycoplasma pneumoniae[J]. BMC Genomics, 2015, 16(1): 610.
doi: 10.1186/s12864-015-1801-0 |
[5] |
Zhang WZ, Zhang SJ, Wang QY, et al. Outbreak of macrolide-resistant Mycoplasma pneumoniae in a primary school in Beijing, China in 2018[J]. BMC Infect Dis, 2019, 19(1): 871.
doi: 10.1186/s12879-019-4473-6 |
[6] |
Leng M, Yang J, Zhou J. The molecular characteristics, diagnosis, and treatment of macrolide-resistant Mycoplasma pneumoniae in children[J]. Front Pediatr, 2023, 11: 1115009.
doi: 10.3389/fped.2023.1115009 |
[7] |
Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas[J]. Microbiol Mol Biol Rev, 1998, 62(4): 1094-1156.
doi: 10.1128/MMBR.62.4.1094-1156.1998 |
[8] |
Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the respiratory tract and beyond[J]. Clin Microbiol Rev, 2017, 30(3): 747-809.
doi: 10.1128/CMR.00114-16 pmid: 28539503 |
[9] |
Chen J, Zhang J, Lu Z, et al. Mycoplasma pneumoniae among Chinese outpatient children with mild respiratory tract infections during the coronavirus disease 2019 pandemic[J]. Microbiol Spectr, 2022, 10(1): e0155021.
doi: 10.1128/spectrum.01550-21 |
[10] |
Oishi T, Ouchi K. Recent trends in the epidemiology, diagnosis, and treatment of macrolide-resistant Mycoplasma pneumoniae[J]. J Clin Med, 2022, 11(7): 1782.
doi: 10.3390/jcm11071782 |
[11] |
Han X, Li S, Lu S, et al. Amplification of 16S rDNA by nested PCR for measurement of Mycoplasma pneumoniae DNA over time: clinical application[J]. J Med Microbiol, 2012, 61(Pt 3): 426-430.
doi: 10.1099/jmm.0.030098-0 |
[12] |
Nilsson AC, Björkman P, Persson K. Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection[J]. BMC Microbiol, 2008, 8: 93.
doi: 10.1186/1471-2180-8-93 pmid: 18547431 |
[13] |
Chen J, Ji F, Yin Y, et al. Time to Mycoplasma pneumoniae RNA clearance for wheezy vs. non-wheezy young children with community-acquired pneumonia[J]. J Trop Pediatr, 2021, 67(1): fmaa109.
doi: 10.1093/tropej/fmaa109 |
[14] |
Suzuki Y, Shimotai Y, Itagaki T, et al. Development of macrolide resistance-associated mutations after macrolide treatment in children infected with Mycoplasma pneumoniae[J]. J Med Microbiol, 2017, 66(11): 1531-1538.
doi: 10.1099/jmm.0.000582 pmid: 28984229 |
[15] |
Zhao F, Li J, Liu J, et al. Antimicrobial susceptibility and molecular characteristics of Mycoplasma pneumoniae isolates across different regions of China[J]. Antimicrob Resist Infect Control, 2019, 8: 143.
doi: 10.1186/s13756-019-0576-5 |
[16] |
Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae[J]. Front Microbiol, 2016, 7: 693.
doi: 10.3389/fmicb.2016.00693 pmid: 27242718 |
[17] |
Lin K, Zahlanie Y, Ortwine JK, et al. Decreased outpatient fluoroquinolone prescribing using a multimodal antimicrobial stewardship initiative[J]. Open Forum Infect Dis, 2020, 7(6): ofaa182.
doi: 10.1093/ofid/ofaa182 |
[18] |
Chen J, Qi X, Yin Y, et al. Effects of minocycline on macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children: a single-center retrospective study[J]. Transl Pediatr, 2021, 10(11): 2997-3004.
doi: 10.21037/tp |
[19] | Okada T, Morozumi M, Tajima T, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children Clin Infect Dis, 2012, 55(12): 1642-1649. |
[20] |
Volovitz B, Shkap R, Amir J, et al. Absence of tooth staining with doxycycline treatment in young children[J]. Clin Pediatr (Phila), 2007, 46(2): 121-126.
doi: 10.1177/0009922806290026 |
[21] | Fernald GW. Immunologic mechanisms suggested in the association of M. pneumoniae infection and extrapulmonary disease: a review[J]. Yale J Biol Med, 1983, 56(5-6): 475-479. |
[22] |
Izumikawa K. Clinical features of severe or fatal Mycoplasma pneumoniae pneumonia[J]. Front Microbiol, 2016, 7: 800.
doi: 10.3389/fmicb.2016.00800 pmid: 27313568 |
[23] |
Taves MD, Ashwell JD. Glucocorticoids in T cell deve-lopment, differentiation and function[J]. Nat Rev Immunol, 2021, 21(4): 233-243.
doi: 10.1038/s41577-020-00464-0 |
[24] |
Sendi P, Graber P, Lepère F, et al. Mycoplasma pneumoniae infection complicated by severe mucocutaneous lesions[J]. Lancet Infect Dis, 2008, 8(4): 268.
doi: 10.1016/S1473-3099(08)70068-9 |
[25] |
You SY, Jwa HJ, Yang EA, et al. Effects of methyl-prednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children[J]. Allergy Asthma Immunol Res, 2014, 6(1): 22-26.
doi: 10.4168/aair.2014.6.1.22 |
[26] |
Sun LL, Ye C, Zhou YL, et al. Meta-analysis of the clinical efficacy and safety of high- and low-dose methylprednisolone in the treatment of children with severe Mycoplasma pneumoniae pneumonia[J]. Pediatr Infect Dis J, 2020, 39(3): 177-183.
doi: 10.1097/INF.0000000000002529 |
[27] |
Wu X, Lu W, Wang T, et al. Optimization strategy for the early timing of bronchoalveolar lavage treatment for children with severe Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2023, 23(1): 661.
doi: 10.1186/s12879-023-08619-9 |
[28] |
Patrucco F, Failla G, Ferrari G, et al. Bronchoscopy during COVID-19 pandemic, ventilatory strategies and procedure measures[J]. Panminerva Med, 2021, 63(4): 529-538.
doi: 10.23736/S0031-0808.21.04533-X pmid: 34606187 |
[29] |
Zhou Y, Wang J, Chen W, et al. Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2020, 20(1): 633.
doi: 10.1186/s12879-020-05356-1 |
[30] |
Liu J, He R, Wu R, et al. Mycoplasma pneumoniae pneumonia associated thrombosis at Beijing children's hospital[J]. BMC Infect Dis, 2020, 20(1): 51.
doi: 10.1186/s12879-020-4774-9 |
[31] |
Chen S, Ding Y, Vinturache A, et al. Pulmonary embolism associated with mycoplasma in a child[J]. Lancet Infect Dis, 2020, 20(11): 1347.
doi: 10.1016/S1473-3099(20)30253-X pmid: 33098782 |
[32] |
Rajpurkar M, Biss T, Amankwah EK, et al. Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. A systematic review[J]. Thromb Haemost, 2017, 117(6): 1199-1207.
doi: 10.1160/TH16-07-0529 |
[33] |
Song S, Xu Y. A retrospective study of the clinical characteristics of 9 children with pulmonary embolism associated with Mycoplasma pneumoniae pneumonia[J]. BMC Pediatr, 2023, 23(1): 370.
doi: 10.1186/s12887-023-04188-7 |
[34] |
Witmer CM, Steenhoff AP, Shah SS, et al. Mycoplasma pneumoniae, splenic infarct, and transient antiphospholipid antibodies: a new association?[J]. Pediatrics, 2007, 119(1): e292-e295.
doi: 10.1542/peds.2006-1340 pmid: 17178923 |
[35] |
Snowden N, Wilson PB, Longson M, et al. Antiphospholipid antibodies and Mycoplasma pneumoniae infection[J]. Postgrad Med J, 1990, 66(775): 356-362.
pmid: 2371184 |
[36] |
Han C, Zhang T, Zheng J, et al. Analysis of the risk factors and clinical features of Mycoplasma pneumoniae pneumonia with embolism in children: a retrospective study[J]. Ital J Pediatr, 2022, 48(1): 153.
doi: 10.1186/s13052-022-01344-0 |
[37] |
Moore AJE, Wachsmann J, Chamarthy MR, et al. Imaging of acute pulmonary embolism: an update[J]. Cardiovasc Diagn Ther, 2018, 8(3): 225-243.
doi: 10.21037/cdt |
[38] |
Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism[J]. Blood Adv, 2020, 4(19): 4693-4738.
doi: 10.1182/bloodadvances.2020001830 pmid: 33007077 |
[39] |
Fu Y, Zhang TQ, Dong CJ, et al. Clinical characteristics of 14 pediatric Mycoplasma pneumoniae pneumonia associated thrombosis: a retrospective study[J]. BMC Cardiovasc Disord, 2023, 23(1): 1.
doi: 10.1186/s12872-022-03030-9 |
[40] |
Chen L, Yin J, Liu X, et al. Thromboembolic complications of Mycoplasma pneumoniae pneumonia in children[J]. Clin Respir J, 2023, 17(3): 187-196.
doi: 10.1111/crj.v17.3 |
[41] |
Sheng CQ, Yang CF, Ao Y, et al. Mycoplasma pneumoniae pneumonia with pulmonary embolism: a study on pediatric cases in Jilin province of China[J]. Exp Ther Med, 2021, 21(3): 201.
doi: 10.3892/etm |
[1] | 顾雨瞳, 杨芬, 叶剑敏, 华丽, 李菁, 丁国栋. 住院患儿肺炎支原体肺炎大环内酯类耐药情况及临床诊治[J]. 临床儿科杂志, 2024, 42(3): 182-186. |
[2] | 高龙飞, 张景丽, 吴晓杰, 吴会芳, 段晨初, 康军聪, 张中平. IL-17A对于儿童难治性肺炎支原体肺炎预测作用[J]. 临床儿科杂志, 2023, 41(5): 366-369. |
[3] | 刘峰. 肺炎支原体肺炎与预后相关的临床指标[J]. 临床儿科杂志, 2022, 40(4): 247-251. |
[4] | 黄坤玲,牛波,路素坤,等. 肺炎支原体肺炎并发心腔内血栓、肺栓塞1 例并文献复习[J]. 临床儿科杂志, 2021, 39(6): 421-. |
[5] | 于聪,吕伟,张晓英. MP 23S rRNA A2063G 基因变异的社区获得性肺炎患儿临床表型与胸部影像的关系[J]. 临床儿科杂志, 2021, 39(4): 265-. |
[6] | 王崇杰,骆学勤,罗健,等. 46 例重症肺炎支原体肺炎合并胸腔积液患儿临床及预后分析[J]. 临床儿科杂志, 2020, 38(4): 269-. |
[7] | 谢晓虹,王崇杰,张光莉,等. 肺炎支原体肺炎患儿支气管肺泡灌洗液细胞因子特点及相关性分析[J]. 临床儿科杂志, 2020, 38(12): 884-. |
[8] | 马彩霞,陈镜龙,陆泳,等. 肺泡灌洗液宏基因组测序在儿童重症肺炎支原体肺炎混合感染中的诊断价值[J]. 临床儿科杂志, 2020, 38(12): 891-. |
[9] | 陈秋雨,陆敏. 疱疹病毒抗体阳性肺炎支原体肺炎患儿免疫状况及临床特征[J]. 临床儿科杂志, 2020, 38(1): 1-. |
[10] | 易茜,吴毅,李媛媛,等. 肺炎支原体肺炎闭塞性支气管炎1 例报告并文献复习[J]. 临床儿科杂志, 2019, 37(6): 423-. |
[11] | 万姣,江李莉,索风涛,等. 鼻咽抽吸物MP-DNA拷贝数与肺炎支原体肺炎临床表现的关系[J]. 临床儿科杂志, 2019, 37(2): 81-. |
[12] | 王欣,杨花芳,王唯一,郑华城. 儿童肺炎支原体肺炎并发基底动脉尖综合征1 例报告[J]. 临床儿科杂志, 2019, 37(1): 34-38. |
[13] | 翟佳羽, 林烈桔, 麦朗君, 符学兴, 苏显都. 难治性肺炎支原体肺炎患儿临床特点及危险因素分析[J]. 临床儿科杂志, 2017, 35(8): 569-. |
[14] | 丁莹, 雷小丽, 孙旦, 李玉琴, 储矗, 陈正荣, 季伟, 周卫芳. 肺炎支原体肺炎外周血miRNAs 差异表达谱的筛选与验证[J]. 临床儿科杂志, 2017, 35(2): 90-. |
[15] | 陆燕红, 张新星, 严永东, 顾文婧, 陈正荣, 朱灿红, 王宇清, 黄莉, 邵雪君, 季伟. 混合感染因素对难治性肺炎支原体肺炎的影响[J]. 临床儿科杂志, 2017, 35(2): 81-. |
|